CRVS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 19:33):

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies...

Stats
Tagesvolumen	77 003.00
Durchschnittsvolumen	199 637
Marktkapitalisierung	76.01M
EPS	$0 ( 2024-03-26 )
Nächstes Ertragsdatum	( $-0.120 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.77
ATR14	$0.0140 (0.92%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-28	Arcara Jeffrey	Buy	400 000	Stock Option (Right to Buy)
2024-02-02	Arcara Jeffrey	Buy	0
2023-12-06	Miller Richard A Md	Buy	500 000	Stock Option (Right to Buy)
2023-12-06	Lea Leiv	Buy	200 000	Stock Option (Right to Buy)
2023-12-06	Jones William Benton	Buy	200 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 8 310 910 \| Sell: 8 757 350

Volumen Korrelation

Lang: -0.27 (neutral)

Kurz: 0.77 (moderate)

Signal:(47.321) Neutral

Corvus Pharmaceuticals Korrelation

10 Am meisten positiv korreliert
GNLN	0.95
VTGN	0.947
AQST	0.943
LIXT	0.936
OMCL	0.924
FLGC	0.921
BBLG	0.92
NNOX	0.917
NERV	0.914
APTO	0.914

10 Am meisten negativ korreliert
PRAA	-0.957
PEBK	-0.95
IEP	-0.931
LEXX	-0.928
FOXF	-0.927
CRWS	-0.916
PROV	-0.911
FARO	-0.911
VORB	-0.91
PINC	-0.909

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Corvus Pharmaceuticals Korrelation - Währung/Rohstoff

0.46
( neutral )

0.37
( neutral )

0.00
( neutral )

0.56
( weak )

-0.33
( neutral )

-0.42
( neutral )

Corvus Pharmaceuticals Finanzdaten

Annual	2023
Umsatz:	$0
Bruttogewinn:	$-151 000 (0.00 %)
EPS:	$-0.560

FY	2023
Umsatz:	$0
Bruttogewinn:	$-151 000 (0.00 %)
EPS:	$-0.560

FY	2022
Umsatz:	$0
Bruttogewinn:	$-367 000 (0.00 %)
EPS:	$-1.080

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.030

Financial Reports:

No articles found.

Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.